Predicting Antimicrobial Resistance Prevalence and Incidence from Indicators of Antimicrobial Use: What Is the Most Accurate Indicator for Surveillance in Intensive Care Units?

被引:5
|
作者
Fortin, Elise [1 ,2 ,3 ]
Platt, Robert W. [1 ]
Fontela, Patricia S. [1 ,4 ]
Buckeridge, David L. [1 ]
Quach, Caroline [1 ,2 ,3 ,4 ]
机构
[1] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada
[2] Inst Natl Sante Publ Quebec, Direct Risques Biol & Sante Travail, Quebec City, PQ, Canada
[3] Inst Natl Sante Publ Quebec, Direct Risques Biol & Sante Travail, Montreal, PQ, Canada
[4] McGill Univ, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ H3H 1P3, Canada
来源
PLOS ONE | 2015年 / 10卷 / 12期
关键词
ANTIBIOTIC USE; PATIENT-DAYS; DRUG-USE; HOSPITALS; ASSOCIATION; QUALITY;
D O I
10.1371/journal.pone.0145088
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective The optimal way to measure antimicrobial use in hospital populations, as a complement to surveillance of resistance is still unclear. Using respiratory isolates and antimicrobial prescriptions of nine intensive care units (ICUs), this study aimed to identify the indicator of antimicrobial use that predicted prevalence and incidence rates of resistance with the best accuracy. Methods Retrospective cohort study including all patients admitted to three neonatal (NICU), two pediatric (PICU) and four adult ICUs between April 2006 and March 2010. Ten different resistance / antimicrobial use combinations were studied. After adjustment for ICU type, indicators of antimicrobial use were successively tested in regression models, to predict resistance prevalence and incidence rates, per 4-week time period, per ICU. Binomial regression and Poisson regression were used to model prevalence and incidence rates, respectively. Multiplicative and additive models were tested, as well as no time lag and a one 4-week-period time lag. For each model, the mean absolute error (MAE) in prediction of resistance was computed. The most accurate indicator was compared to other indicators using t-tests. Results Results for all indicators were equivalent, except for 1/20 scenarios studied. In this scenario, where prevalence of carbapenem-resistant Pseudomonas sp. was predicted with carbapenem use, recommended daily doses per 100 admissions were less accurate than courses per 100 patient-days (p = 0.0006). Conclusions A single best indicator to predict antimicrobial resistance might not exist. Feasibility considerations such as ease of computation or potential external comparisons could be decisive in the choice of an indicator for surveillance of healthcare antimicrobial use.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Nationwide surveillance of antimicrobial resistance among Haemophilus influenzae and Streptococcus pneumoniae in intensive care units in Taiwan
    S.-S. Jean
    P.-R. Hsueh
    W.-S. Lee
    H.-T. Chang
    M.-Y. Chou
    I.-S. Chen
    J.-H. Wang
    C.-F. Lin
    J.-M. Shyr
    W.-C. Ko
    J.-J. Wu
    Y.-C. Liu
    W.-K. Huang
    L.-J. Teng
    C.-Y. Liu
    European Journal of Clinical Microbiology & Infectious Diseases, 2009, 28
  • [32] Evolution of antimicrobial resistance in Gram negative bacilli from intensive care units in Colombia
    Hernandez-Gomez, Cristhian
    Blanco, Vctor M.
    Motoa, Gabriel
    Correa, Adriana
    Maya, Juan Jose
    de la Cadena, Elsa
    Perenguez, Marcela
    Rojas, Laura
    Hernandez, Alejandra
    Vallejo, Marta
    Villegas, Maria Virginia
    BIOMEDICA, 2014, 34 : 91 - 100
  • [33] Fighting Antimicrobial Resistance in Neonatal Intensive Care Units: Rational Use of Antibiotics in Neonatal Sepsis
    Rallis, Dimitrios
    Giapros, Vasileios
    Serbis, Anastasios
    Kosmeri, Chrysoula
    Baltogianni, Maria
    ANTIBIOTICS-BASEL, 2023, 12 (03):
  • [34] Neonatologists' Perceptions of Antimicrobial Resistance and Stewardship in Neonatal Intensive Care Units
    Patel, Sameer J.
    Rosen, Emily
    Zaoutis, Theoklis
    Prasad, Priya
    Saiman, Lisa
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2010, 31 (12): : 1298 - 1300
  • [35] Surveillance of antibiotic use and bacterial resistance in intensive care units
    Meyer, E.
    Schwab, F.
    Schroeren-Boersch, B.
    Gastmeier, P.
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2008, 51 (08) : 926 - 935
  • [36] A surveillance study of antimicrobial resistance of Gram-negative bacteria isolated from intensive care units in eight hospitals in Turkey
    Günseren, F
    Mamikoglu, L
    Öztürk, S
    Yücesoy, M
    Biberoglu, K
    Yulug, N
    Doganay, M
    Sümerkan, B
    Kocagöz, S
    Ünal, S
    Çetin, S
    Çalangu, S
    Köksal, I
    Leblebicioglu, H
    Günaydin, M
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (03) : 373 - 378
  • [37] Point prevalence surveys of antimicrobial use among eight neonatal intensive care units in India: 2016
    Gandra, Sumanth
    Alvarez-Uria, Gerardo
    Murki, Srinivas
    Singh, Sanjeev K.
    Kanithi, Ravishankar
    Jinka, Dasaratha R.
    Chikkappa, Ashok K.
    Subramanian, Sreeram
    Sharma, Anita
    Dharmapalan, Dhanya
    Kandraju, Hemasree
    Vasudevan, Anil Kumar
    Tunga, Onkaraiah
    Akula, Akhila
    Hsia, Yingfen
    Sharland, Mike
    Laxminarayan, Ramanan
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 71 : 20 - 24
  • [38] A nationwide survey of intravenous antimicrobial use in intensive care units in Japan
    Ohnuma, Tetsu
    Hayashi, Yoshiro
    Yamashita, Kazuto
    Marquess, John
    Lefor, Alan Kawarai
    Sanui, Masamitsu
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2018, 51 (04) : 636 - 641
  • [39] Choosing wisely: what is the actual role of antimicrobial stewardship in Intensive Care Units?
    Montrucchio, Giorgia
    Sales, Gabriele
    Corcione, Silvia
    De Rosa, Francesco G.
    Brazzi, Luca
    MINERVA ANESTESIOLOGICA, 2019, 85 (01) : 71 - 82
  • [40] Duration of antimicrobial therapy for nosocomial pneumonia: possible strategies for minimizing antimicrobial use in intensive care units
    Dugan, HA
    MacLaren, R
    Jung, R
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2003, 28 (02) : 123 - 129